Login to Your Account


CAR-T Immunotherapy moving fast, avoiding Provenge pitfalls

By Nuala Moran
Staff Writer

Thursday, November 13, 2014

LONDON – The compelling clinical data and widespread interest in chimeric antigen receptor T-cell immunotherapies is infecting regulatory agencies worldwide and they are vying to be first to review one of those products, according to Usman Azam, global head of cell and gene therapies at Novartis AG.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription